<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01398111</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-1101-PR-0056</org_study_id>
    <secondary_id>2011-001552-11</secondary_id>
    <nct_id>NCT01398111</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers</brief_title>
  <acronym>TRIPLE 1</acronym>
  <official_title>Open-label, Randomized, Single-dose, Placebo-controlled, 4-way Crossover Study to Investigate the Pharmacokinetic Interaction of Glycopyrrolate and Formoterol in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be carried out in healthy volunteers with the primary objective to evaluate
      the pharmacokinetic interaction between Glyco and Formoterol administered using a pressurised
      metered dose inhaler (pMDI).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: formoterol and glyco AUC0-t</measure>
    <time_frame>from pre-dose to 32 hours after administration</time_frame>
    <description>Area under the plasma concentration curve observed from administration up to the last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: formoterol and glyco Cmax</measure>
    <time_frame>from pre-dose to 32 hours after administration</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional pharmacokinetic variables</measure>
    <time_frame>from pre-dose to 32 hours post dose</time_frame>
    <description>Plasma Glyco AUC0-30min, AUC0-32h, AUC0-inf, tmax and t1/2 - Plasma Formoterol AUC0-30min, AUC0-24h, AUC0-inf, tmax and t1/2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum potassium</measure>
    <time_frame>From pre-dose to 24 hours after administration</time_frame>
    <description>Serum potassium Cmin, tmin and AUC0-24h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>from pre-dose to 24 hours after administration</time_frame>
    <description>Plasma glucose Cmax, tmax and AUC0-24h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function</measure>
    <time_frame>from pre-dose to 1 hour after administration</time_frame>
    <description>FEV1 in order to assess potential occurrence of paradoxical bronchospasm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>from pre-dose to 24 hours after administration</time_frame>
    <description>heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>from pre-dose to 24 hours after administration</time_frame>
    <description>12-lead ECG parameters: HR, RR, PR, QRS, QT, QTcB, QTcF</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Treatment R2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment R1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate + Formoterol</intervention_name>
    <description>glycopyrrolate pMDI + formoterol pMDI</description>
    <arm_group_label>Treatment T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>glycopyrrolate pMDI</description>
    <arm_group_label>Treatment R1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>formoterol pMDI</description>
    <arm_group_label>Treatment R2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo pMDI</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females healthy volunteers aged 18-65 years will be included in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lien Gheyle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology Unit at SGS Life Sciences - Antwerpen (Belgium)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology Unit - SGS Life Science Services</name>
      <address>
        <city>Antwerpen</city>
        <state>Lange Beeldekensstraat 267</state>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>July 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2011</study_first_posted>
  <last_update_submitted>April 2, 2012</last_update_submitted>
  <last_update_submitted_qc>April 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

